This segment focused on the research and development of novel treatments for rare endocrine diseases. Millendo's primary focus was on developing disease-modifying therapies for conditions with significant unmet medical needs. Research and development activities included preclinical studies, clinical trials, and regulatory submissions. The company utilized small molecule drug discovery and development methodologies. The therapeutic areas covered included Prader-Willi syndrome, classic congenital adrenal hyperplasia, and the treatment of vasomotor symptoms in menopausal women. The goal was to improve the quality of life for patients suffering from these rare conditions. Market positioning was based on being a late-stage biopharmaceutical company with a focus on orphan diseases. The company aimed to address the unmet needs of patients with rare endocrine disorders. This segment involved partnerships and collaborations to advance its pipeline and expand its reach within the rare disease space.